1142 related articles for article (PubMed ID: 27435662)
1. LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer.
Stanisavljević L; Myklebust MP; Leh S; Dahl O
Acta Oncol; 2016 Dec; 55(12):1425-1433. PubMed ID: 27435662
[TBL] [Abstract][Full Text] [Related]
2. Increased expression of CD133 is a strong predictor of poor outcome in stage I colorectal cancer patients.
Reggiani Bonetti L; Migaldi M; Caredda E; Boninsegna A; Ponz De Leon M; Di Gregorio C; Barresi V; Scannone D; Danese S; Cittadini A; Sgambato A
Scand J Gastroenterol; 2012 Oct; 47(10):1211-7. PubMed ID: 22856425
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer.
Iinuma H; Watanabe T; Mimori K; Adachi M; Hayashi N; Tamura J; Matsuda K; Fukushima R; Okinaga K; Sasako M; Mori M
J Clin Oncol; 2011 Apr; 29(12):1547-55. PubMed ID: 21422427
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical Expression of CD133 and LGR5 in Ulcerative Colitis-associated Colorectal Cancer and Dysplasia.
Kazama S; Kishikawa J; Tanaka T; Hata K; Kawai K; Nozawa H; Ishihara S
In Vivo; 2019; 33(4):1279-1284. PubMed ID: 31280219
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of leucine-rich-repeat-containing G-protein-coupled receptor 5, an intestinal stem cell marker, in gastric carcinomas.
Jang BG; Lee BL; Kim WH
Gastric Cancer; 2016 Jul; 19(3):767-77. PubMed ID: 26386561
[TBL] [Abstract][Full Text] [Related]
6. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
[TBL] [Abstract][Full Text] [Related]
7. A gene signature distinguishing CD133hi from CD133- colorectal cancer cells: essential role for EGR1 and downstream factors.
Ernst A; Aigner M; Nakata S; Engel F; Schlotter M; Kloor M; Brand K; Schmitt S; Steinert G; Rahbari N; Koch M; Radlwimmer B; Weitz J; Lichter P
Pathology; 2011 Apr; 43(3):220-7. PubMed ID: 21436631
[TBL] [Abstract][Full Text] [Related]
8. Nuclear Notch3 expression is associated with tumor recurrence in patients with stage II and III colorectal cancer.
Ozawa T; Kazama S; Akiyoshi T; Murono K; Yoneyama S; Tanaka T; Tanaka J; Kiyomatsu T; Kawai K; Nozawa H; Kanazawa T; Yamaguchi H; Ishihara S; Sunami E; Kitayama J; Morikawa T; Fukayama M; Watanabe T
Ann Surg Oncol; 2014 Aug; 21(8):2650-8. PubMed ID: 24728738
[TBL] [Abstract][Full Text] [Related]
9. Differential clinical benefits of 5-fluorouracil-based adjuvant chemotherapy for patients with stage III colorectal cancer according to CD133 expression status.
Shikina A; Shinto E; Hashiguchi Y; Ueno H; Naito Y; Okamoto K; Kubo T; Fukazawa S; Yamamoto J; Hase K
Jpn J Clin Oncol; 2014 Jan; 44(1):42-8. PubMed ID: 24244031
[TBL] [Abstract][Full Text] [Related]
10. Mismatch repair protein expression is an independent prognostic factor in sporadic colorectal cancer.
Ohrling K; Edler D; Hallström M; Ragnhammar P
Acta Oncol; 2010 Aug; 49(6):797-804. PubMed ID: 20307245
[TBL] [Abstract][Full Text] [Related]
11. CD133 expression predicts for non-response to chemotherapy in colorectal cancer.
Ong CW; Kim LG; Kong HH; Low LY; Iacopetta B; Soong R; Salto-Tellez M
Mod Pathol; 2010 Mar; 23(3):450-7. PubMed ID: 20081809
[TBL] [Abstract][Full Text] [Related]
12. Defective Mismatch Repair Status was not Associated with DFS and OS in Stage II Colon Cancer Treated with Adjuvant Chemotherapy.
Kim JE; Hong YS; Kim HJ; Kim KP; Lee JL; Park SJ; Lim SB; Park IJ; Kim CW; Yoon YS; Yu CS; Kim JC; Hoon KJ; Kim TW
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S630-7. PubMed ID: 26271397
[TBL] [Abstract][Full Text] [Related]
13. Tumour CD133 mRNA expression and clinical outcome in surgically resected colorectal cancer patients.
Artells R; Moreno I; Díaz T; Martínez F; Gel B; Navarro A; Ibeas R; Moreno J; Monzó M
Eur J Cancer; 2010 Feb; 46(3):642-9. PubMed ID: 20005089
[TBL] [Abstract][Full Text] [Related]
14. Mesenchymal marker and LGR5 expression levels in circulating tumor cells correlate with colorectal cancer prognosis.
Wang W; Wan L; Wu S; Yang J; Zhou Y; Liu F; Wu Z; Cheng Y
Cell Oncol (Dordr); 2018 Oct; 41(5):495-504. PubMed ID: 29949050
[TBL] [Abstract][Full Text] [Related]
15. CD133 expression predicts post-operative recurrence in patients with colon cancer with peritoneal metastasis.
Nagata H; Ishihara S; Kishikawa J; Sonoda H; Murono K; Emoto S; Kaneko M; Sasaki K; Otani K; Nishikawa T; Tanaka T; Kiyomatsu T; Hata K; Kawai K; Nozawa H
Int J Oncol; 2018 Mar; 52(3):721-732. PubMed ID: 29328371
[TBL] [Abstract][Full Text] [Related]
16. Lysosomal acid phosphatase 2 is an unfavorable prognostic factor but is associated with better survival in stage II colorectal cancer patients receiving chemotherapy.
Lee YC; Su CY; Lin YF; Lin CM; Fang CY; Lin YK; Hsiao M; Chen CL
Oncotarget; 2017 Feb; 8(7):12120-12132. PubMed ID: 28076332
[TBL] [Abstract][Full Text] [Related]
17. Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy.
Edler D; Glimelius B; Hallström M; Jakobsen A; Johnston PG; Magnusson I; Ragnhammar P; Blomgren H
J Clin Oncol; 2002 Apr; 20(7):1721-8. PubMed ID: 11919227
[TBL] [Abstract][Full Text] [Related]
18. Angiogenesis-Related Markers and Prognosis After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Metastatic Colorectal Cancer.
de Cuba EM; de Hingh IH; Sluiter NR; Kwakman R; Coupé VM; Beliën JA; Verwaal VJ; Meijerink WJ; Delis-van Diemen PM; Bonjer HJ; Meijer GA; Te Velde EA
Ann Surg Oncol; 2016 May; 23(5):1601-8. PubMed ID: 26727921
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
20. Lgr5 over-expression is positively related to the tumor progression and HER2 expression in stage pTNM IV colorectal cancer.
Gao FJ; Chen JY; Wu HY; Shi J; Chen M; Fan XS; Huang Q
Int J Clin Exp Pathol; 2014; 7(4):1572-9. PubMed ID: 24817953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
